Patents by Inventor Youyi Peng
Youyi Peng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220363649Abstract: The invention relates in one aspect to compounds, and compositions comprising such compounds, that can be used to treat and/or prevent pain in a subject. In certain embodiments, the subject is a mammal. In yet other embodiments, the mammal is human.Type: ApplicationFiled: June 10, 2021Publication date: November 17, 2022Inventors: Youyi Peng, William J. Welsh
-
Patent number: 11491150Abstract: The disclosure relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., diabetes mellitus, chronic kidney disease, acute kidney failure, and reduction of blood glucose levels.Type: GrantFiled: May 22, 2018Date of Patent: November 8, 2022Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Youyi Peng, Lawrence P. Wennogle, Qiang Zhang
-
Patent number: 10851096Abstract: Certain compounds of formula I: I and salts including pharmaceutically acceptable salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using a compound of formula I.Type: GrantFiled: June 16, 2017Date of Patent: December 1, 2020Assignees: Rutgers, The State University of New Jersey, The Curators of the University of MissouriInventors: William J. Welsh, Raymond Birge, Vladyslav Kholodovych, Youyi Peng, Thomas Walter Comollo, Stanley G. Kimani, Kamlendra Singh
-
Publication number: 20190127361Abstract: Certain compounds of formula I: I and salts including pharmaceutically acceptable salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using a compound of formula I.Type: ApplicationFiled: June 16, 2017Publication date: May 2, 2019Applicants: Rutgers, The State University of New Jersey, The Curators of the University of MissouriInventors: William J. Welsh, Raymond Birge, Vladyslav Kholodovych, Youyi Peng, Thomas Walter Comollo, Stanley G. Kimani, Kamlendra Singh
-
Publication number: 20180333403Abstract: The disclosure relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., diabetes mellitus, chronic kidney disease, acute kidney failure, and reduction of blood glucose levels.Type: ApplicationFiled: May 22, 2018Publication date: November 22, 2018Inventors: Peng LI, Youyi PENG, John TOMESCH, Lawrence P. WENNOGLE, Qiang ZHANG
-
Patent number: 9944648Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.Type: GrantFiled: January 9, 2015Date of Patent: April 17, 2018Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Qiang Zhang, Youyi Peng, Peng Li, J. David Beard, Lawrence P. Wennogle, John Tomesch
-
Patent number: 9708294Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.Type: GrantFiled: January 11, 2016Date of Patent: July 18, 2017Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Youyi Peng, John Tomesch, Lawrence P. Wennogle, Qiang Zhang
-
Publication number: 20170190703Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.Type: ApplicationFiled: January 9, 2015Publication date: July 6, 2017Applicant: Intra-Cellular Therapies, Inc.Inventors: Qiang Zhang, Youyi Peng, Peng Li, J. David Beard, Lawrence P. Wennogle, John Tomesch
-
Publication number: 20160326179Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.Type: ApplicationFiled: January 9, 2015Publication date: November 10, 2016Applicant: Intra-Cellular Therapies, Inc.Inventors: Qiang Zhang, Youyi Peng, Peng Li, J. David Beard, Lawrence P. Wennogle, John Tomesch
-
Patent number: 9469625Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.Type: GrantFiled: June 22, 2012Date of Patent: October 18, 2016Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Youyi Peng, John Tomesch, Lawrence P. Wennogle, Qiang Zhang
-
Patent number: 9452160Abstract: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.Type: GrantFiled: June 17, 2015Date of Patent: September 27, 2016Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Youyi Peng, Lawrence P. Wennogle, Qiang Zhang, John Tomesch
-
Publication number: 20160237061Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.Type: ApplicationFiled: January 11, 2016Publication date: August 18, 2016Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng LI, Youyi PENG, John TOMESCH, Lawrence P. WENNOGLE, Qiang ZHANG
-
Publication number: 20160008343Abstract: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.Type: ApplicationFiled: June 17, 2015Publication date: January 14, 2016Inventors: Youyi PENG, Lawrence P. WENNOGLE, Qiang ZHANG, John TOMESCH
-
Patent number: 9108949Abstract: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.Type: GrantFiled: June 22, 2012Date of Patent: August 18, 2015Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Youyi Peng, Lawrence P. Wennogle, Qiang Zhang, John Tomesch
-
Publication number: 20140205595Abstract: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.Type: ApplicationFiled: June 22, 2012Publication date: July 24, 2014Inventors: Youyi Peng, Lawrence P. Wennogle, Qing Zhang, John Tomesch
-
Publication number: 20140205596Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.Type: ApplicationFiled: June 22, 2012Publication date: July 24, 2014Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Youyi Peng, John Tomesch, Lawrence P. Wennogle, Qiang Zhang
-
Patent number: 8569350Abstract: Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof.Type: GrantFiled: February 23, 2012Date of Patent: October 29, 2013Assignee: Rutgers, The State University of New JerseyInventors: William J. Welsh, Youyi Peng, Xin Wang, Susan M. Keenan, Qiang Zhang, Sonia Arora
-
Publication number: 20120149744Abstract: Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof.Type: ApplicationFiled: February 23, 2012Publication date: June 14, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: William J. Welsh, Youyi Peng, Xin Wang, Susan M. Keenan, Qiang Zhang, Sonia Arora
-
Patent number: 8188128Abstract: Opioid receptor compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a condition mediated by an opioid receptor by administering an effective amount of the opioid receptor compound to a patient in need thereof.Type: GrantFiled: May 12, 2006Date of Patent: May 29, 2012Assignee: The University of Medicine and Dentistry of New JerseyInventors: William J. Welsh, Youyi Peng, Qiang Zhang, Susan M. Keenan, Sonia Arora
-
Patent number: 8143299Abstract: Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof.Type: GrantFiled: October 25, 2005Date of Patent: March 27, 2012Assignee: University of Medicine and Dentistry of New JerseyInventors: William J. Welsh, Youyi Peng, Xin Wang, Susan M. Keenan, Qiang Zhang, Sonia Arora